New psychoactive substances in prison. by unknown
Results from an EMCDDA trendspotter study
June 2018
RAPID COMMUNICATION
New psychoactive 
substances in prison

Results from an EMCDDA trendspotter study
June 2018
New psychoactive 
substances in prison
Recommended citation:  
European Monitoring Centre for Drugs and Drug Addiction (2018), New psychoactive substances in prison, EMCDDA 
Rapid Communication, Publications Office of the European Union, Luxembourg.
Print ISBN 978-92-9497-317-7 doi:10.2810/492880 TD-01-18-479-EN-C
PDF ISBN 978-92-9497-316-0 doi:10.2810/7247 TD-01-18-479-EN-N
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal 
Tel. +351 211210200 
info@emcdda.europa.eu I www.emcdda.europa.eu
twitter.com/emcdda I facebook.com/emcdda
I Legal notice
This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by 
copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the 
data contained in this document. The contents of this publication do not necessarily reflect the official opinions of 
the EMCDDA’s partners, any EU Member State or any agency or institution of the European Union.
Luxembourg: Publications Office of the European Union, 2018
© European Monitoring Centre for Drugs and Drug Addiction, 2018
Reproduction is authorised provided the source is acknowledged.
Photo credits: Front cover photos 1 and 3, iStockphotos.com; photo 2, Slovenian National Forensic Laboratory 
(police); photo 4, public domain, author unknown.
For any use or reproduction of photos or other material that is not under the European Monitoring Centre for 
Drugs and Drug Addiction copyright, permission must be sought directly from the copyright holders.
Printed by Imprimerie Centrale in Luxembourg
4 Study rationale and methods
5 Extent and nature of NPS use in prisons in Europe
8 Supply of NPS to prisons
9 NPS-related harms
10 Responses to NPS in prison
11 Key issues
13  Conclusion
13  Acknowledgements
14  References
Authors: Liesbeth Vandam, Prem Borle, Linda Montanari, Tim Surmont,  
Alessandro Pirona, Dagmar Hedrich, Ana Gallegos, Nicola Singleton, Jane Mounteney, 
Paul Griffiths
I Contents
New psychoactive substances in prison
4
I  Study rationale and methods
This publication provides an overview of the latest 
information available on the use of new psychoactive 
substances (NPS) and related problems in European 
prisons based on a rapid information assessment carried 
out by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). The study complements data from 
a range of established sources. The EMCDDA has been 
routinely collecting data on illicit drug use among prisoners 
for over 15 years through a combination of qualitative and 
quantitative monitoring tools, although the primary focus 
has been on controlled substances. The EMCDDA also 
collects information on NPS and, in 2017, was monitoring 
a total of over 670 NPS that have been notified to the EU 
Early Warning System (EWS). The use of NPS by high-risk 
drug users has recently been explored by the EMCDDA 
(2017a). The study found that while consumption levels of 
these drugs were low overall in Europe, the smoking of 
synthetic cannabinoids among some marginalised 
populations, including prisoners, appeared to be an 
emerging but poorly understood problem in many 
European countries.
This study was prompted therefore by the conclusion that 
NPS use among prisoners appears to be a rapidly 
developing phenomenon and there is growing concern in 
some countries that NPS may be responsible for a large 
share of drug-related problems in prison, while appropriate 
responses are mostly lacking. However, empirical data are 
currently scarce and patchy, as monitoring drug use 
among prisoners in general, and NPS use in particular, at 
the European level is challenging due to the different study 
designs applied and limited systematic data collection.
To investigate the extent, nature and impact of these 
developments the EMCDDA carried out a targeted rapid 
information assessment between August and December 
2017. The aim of the study was to map and increase 
understanding of NPS use in prisons in Europe, including 
prevalence and patterns of use, the underlying 
contributing factors, associated harms and market and 
supply features of NPS use in prisons, as well as the 
responses implemented to address NPS-related problems 
in prison settings.
The study used the EMCDDA trendspotter methodology, 
which draws on a range of different investigative 
approaches and utilises data from multiple sources 
(Mounteney et al., 2015). The work was divided into two 
phases (see Figure 1). The first phase, carried out by an 
EMCDDA team, involved data collection through an 
exploratory ‘rapid information request’ among national 
focal points in 30 countries (28 replied), a non-systematic 
review of the international literature, grey literature and 
available EMCDDA monitoring data (‘Literature and data 
review’). This was complemented by internet surveys of 
three groups: an informal network of prison experts (8 
respondents), experts invited to the trendspotter meeting 
(12 respondents) and a selection of national focal points 
(7 respondents) (‘online expert surveys’).
The second phase centred on an expert meeting, held in 
Lisbon on 13 to 14 December 2017. The event was 
attended by 11 invited experts from 9 countries, who 
presented information on the situation in their country, 
participated in two facilitated working groups and 
contributed to an in-depth analysis of the topic, providing 
insights from a range of perspectives including drug 
research and monitoring, user/prisoner representation, law 
enforcement, prison officers, prison administration and 
(prison) health services.
Analysis was based on triangulation of all the information 
sources, with a view to providing as complete and verified 
a picture as possible. The combination of routine and 
survey data with key informant reports and law 
enforcement intelligence provided a rich and in-depth view 
of a rapidly developing phenomenon. This report 
summarises the study findings and conclusions. Where 
results are based on the literature, references are cited; 
otherwise findings are based on EMCDDA and national 
monitoring and the qualitative sources described above. 
The reader should note that a trendspotter study provides 
a rapid and practical method for auditing, analysing and 
reporting on a potentially important developmental area. It 
is therefore intended to act as a catalyst for further 
actions, which may include additional, more formal 
research or monitoring activities, or prompt more timely 
discussions on what implications may exist for policy or 
practice.
FIGURE 1
Trendspotter data gathering methods
Literature and 
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Online expert
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Definitions used in this study
New psychoactive substances — this term is used 
for the purposes of this exercise for both non-
controlled and recently controlled new psychoactive 
substances, in particular (but not exclusively) synthetic 
cannabinoids, synthetic cathinones, new synthetic 
opioids and new benzodiazepines. The reader should 
note that this is a broader definition of NPS than 
usually adopted.
Prison — in this study the term ‘prison’ is used in 
a broad sense to include any place in which prisoners 
are held in custody. It therefore includes prisoners 
with a range of legal statuses, such as, but not limited 
to, detainees who have not yet been tried, juvenile 
prisoners and prisoners who are serving custodial 
sentences.
I  Extent and nature of NPS use in prisons in Europe
I  NPS use in prison: becoming a Europe-wide phenomenon
This study identified reports of NPS use among prisoners 
in 22 European countries. In addition to the United 
Kingdom, where the phenomenon is already well-
documented (HMIP, 2015a; Ralphs et al., 2017), our 
findings suggest that NPS use in prison settings is an issue 
of concern in Germany, Hungary, Latvia, Lithuania, Poland, 
Slovenia and Sweden (8 countries). Furthermore, 
anecdotal reports document NPS use in prisons in 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, 
Finland, France, Greece, Ireland, Italy, Malta, Portugal, 
Romania and Norway (14 countries). For other European 
countries, it remains unclear whether there is no NPS use 
in prison or simply that there is no information on the topic 
available (Figure 2). It should be noted, however, this group 
includes some countries for which other data sources 
suggest relatively high availability, or evidence of problems 
associated with NPS use. When compared to the findings 
of the previous trendspotter study on ‘High-risk drug use 
and new psychoactive substances’ (EMCDDA, 2017a), the 
current study, carried out 1 year later, shows an increase in 
the number of countries reporting the use of NPS in prison 
settings. It remains unclear whether this trend reflects 
actual changes in use, increased availability of NPS in 
prisons or improved monitoring and data collection efforts.
FIGURE 2
NPS use among prisoners in the European Union, Norway 
and Turkey
NPS use in prison
Recognised as 
a concern
Some signs 
reported
Use not 
reported
NB: Based on reports from national experts.
Although country comparisons have to be treated with 
caution, it is possible to make some preliminary 
observations as to the geographical variation of perceived 
NPS use in prison. The results presented here suggest, at 
least, that NPS use in prison is more a recognised issue of 
concern in a number of countries, mainly located in the 
north and east of Europe.
I  Types of NPS used in prison
The term ‘new psychoactive substances’ encompasses 
a wide variety of different types of drugs, with very 
different effects. The four main types reported in prison 
settings are synthetic cannabinoids, synthetic cathinones, 
new benzodiazepines and new synthetic opioids (see ‘New 
psychoactive substances reported in European prisons’, 
page 7). Data on the different groups of NPS used in prison 
are available for 16 countries (see Table 1).
The present study finds that synthetic cannabinoids are 
the most common group of NPS used in prison. Not all 
countries provided information on the type of substances 
used, but of the 16 countries that provided information on 
the type of NPS known to be used in prison all reported the 
use of synthetic cannabinoids (see Table 1). There is very 
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limited information available on the different synthetic 
cannabinoids used in prison, but they are likely to reflect 
the diversity seen overall on the drug market. This is 
supported by forensic testing in Germany, where urine 
samples taken from prisoners often contain more than one 
synthetic cannabinoid.
Synthetic cathinones are the next most common type of 
NPS in prison, with 10 countries reporting their use in 
these settings; fewer reported new synthetic opioids (6 
countries) and new benzodiazepines (4 countries) being 
used in prison (see Table 1).
In recent years, the variety of NPS used in European 
prisons appears to have increased. However, it remains 
unclear to what extent this is related to improved 
monitoring efforts. NPS use in prison should be seen 
within a wider polydrug use context, which may also 
include use of alcohol, established drugs and misuse of 
prescription medicines in prison, with availability in this 
setting as one of the important drivers for use. The 
rationale for choosing specific substances in prison is 
likely often to be explained by pragmatic considerations, 
such as availability and price, rather than the personal 
preferences of the user. In Poland, for instance, a shift 
away from the use of established drugs in prison to the use 
of NPS has been reported. A different pattern, however, 
has been observed in Croatia and the Czech Republic, with 
little demand for, and limited use of, NPS in prison, but 
increasing evidence of misuse of prescription medicines. 
The underlying factors and drivers of these differing 
patterns remain poorly understood and merit further 
formal research investigation.
TABLE 1
Groups of NPS identified by experts as being used in prison
Synthetic cannabinoids Synthetic cathinones New synthetic opioids New benzodiazepines
Finland ● ● ● ●
Latvia ● ● ● ●
Poland ● ● ● ●
Sweden ● ● ● –
Czech Republic ● ● ● –
Italy ● – ● ●
Cyprus ● ● – –
Germany ● ● – –
France ● ● – –
Hungary ● ● – –
Lithuania ● ● – –
Croatia ● – – –
Ireland ● – – –
Norway ● – – –
Slovenia ● – – –
United Kingdom ● – – –
Total 16 10 6 4
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New psychoactive substances reported in European prisons
Synthetic cannabinoids — Synthetic cannabinoids (or 
synthetic cannabinoid receptor agonists) is the general 
name given to a diverse range of substances that act on 
the same brain receptors as tetrahydrocannabinol (THC), 
which is largely responsible for the major psychoactive 
effects of cannabis (Fantegrossi et al., 2014; EMCDDA, 
2017b). Synthetic cannabinoids are frequently sold 
as ‘legal’ replacements for cannabis, although their 
effects are often very different. Typically, synthetic 
cannabinoids are sold as ‘herbal smoking mixtures’. 
Synthetic cannabinoids may also be sold as powders 
and tablets, products that look like cannabis resin and 
e-liquids for use in electronic cigarettes (EMCDDA, 
2017c). Synthetic cannabinoids have sometimes been 
grouped under the street name ‘Spice’ or ‘K2’. Synthetic 
cannabinoids continue to be the largest group of 
new substances monitored by the EMCDDA and are 
becoming increasingly diverse, with 179 detected since 
2008 — including 10 reported in 2017 (EMCDDA, 
2018). A wide range of physical and mental health 
harms have been associated with the use of synthetic 
cannabinoids in the general population (EMCDDA, 
2017d). Synthetic cannabinoids are chemically very 
diverse, and because of difficulties in analytical 
identification, they may be undetected or under-
reported.
Synthetic cathinones — Synthetic cathinones are 
chemically related to cathinone, a naturally occurring 
stimulant under international control, found in the khat 
plant (Catha edulis). These substances have effects 
similar to common illicit stimulant drugs such as 
amphetamine, cocaine and MDMA (EMCDDA, 2015). 
Synthetic cathinones are the second largest group of 
new substances monitored by the EMCDDA, with 130 
detected in total — including 14 detected for the first 
time in 2016 and 12 reported in 2017 (EMCDDA, 2018).
New synthetic opioids — Synthetic opioids are a broad 
family of substances that act on the opioid receptors 
and which include prescription pain relievers and 
anaesthetics. They produce effects such as respiratory 
depression, sedation, euphoria, hypothermia, 
drowsiness and miosis (excessive constriction of the 
pupil of the eye). A total of 38 new synthetic opioids 
have been detected on Europe’s drug market since 
2009, including 13 reported for the first time in 2017. 
This includes 28 fentanyl derivatives, 8 of which were 
reported for the first time in 2016 and 10 in 2017. The 
new fentanyl derivatives are highly potent substances, 
which pose a serious threat to individual and public 
health (EMCDDA, 2018).
New benzodiazepines — New benzodiazepines are 
chemically related to prescription benzodiazepines. 
Some 23 new benzodiazepines are being monitored by 
the EMCDDA — 3 of which were detected for the first 
time in Europe in 2017. Some new benzodiazepines 
are sold as tablets, capsules or powders under their 
own names. In other cases, counterfeiters use these 
substances to produce fake versions of commonly 
prescribed anti-anxiety medicines, such as diazepam 
and alprazolam, which are sold directly on the illicit 
drug market. During 2016, more than 0.5 million 
tablets containing new benzodiazepines, such as 
diclazepam, etizolam, flubromazolam, flunitrazolam 
and fonazepam, were seized — an increase of about 
two-thirds on the number reported in 2015 (EMCDDA, 
2018).
For further information on these substances:  
http://www.emcdda.europa.eu/drug-profiles
I  A wide variation in prevalence estimates
It is not possible to compare NPS prevalence estimates 
across countries, as different definitions, data sources and 
methodologies are used. However, the limited data 
available on reported prevalence rates of NPS use in 
prison suggest a wide range, from less than 2 % of 
prisoners in Portugal ever using any NPS while 
incarcerated (Torres et al., 2015) to over 30 % reporting 
last month use of synthetic cannabinoids in some prisons 
in the United Kingdom (User Voice, 2016). There are some 
indications that across Europe, NPS use may be higher in 
men’s prisons than in women’s prisons, higher in remand 
prisons and lower in high-security prisons.
A project in 10 prisons in the United Kingdom, which 
tested the urine of prisoners, found the prevalence of 
synthetic cannabinoid use among prisoners preparing for 
release to be twice (16 % testing positive) the level 
measured among prisoners at the time of admission (8 % 
positive) (National Offender Management Service, 2015). It 
was the only substance for which the percentage of 
positive drug tests was higher pre-release than upon 
arrival in prison.
New psychoactive substances in prison
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The limited information available suggests increasing 
levels of NPS use across European prisons, but this 
conclusion should be interpreted with caution as it is 
primarily based on expert opinion and qualitative 
information sources.
I  Different user groups
Use of NPS in prison settings in Europe was particularly 
associated with two main groups within the prison 
population. First, some countries reported a group of 
marginalised and socially vulnerable people with long drug 
careers, often homeless and in regular contact with the 
criminal justice system, who use NPS while in prison. There 
are indications that psychiatric comorbidities may be 
common in this group. Second, in some countries NPS use 
appears to be more common among young people who are 
relatively inexperienced users of drugs and may be 
initiating NPS use in prison. In Hungary, for instance, 77 % 
of people in prison that had ever used NPS in their lives 
were under the age of 35. Some of those using NPS for the 
first time in prison may have been using cannabis outside 
prison, and switched to synthetic cannabinoids inside 
prison for a variety of reasons (see below). Young prisoners 
using NPS may be particularly vulnerable to bullying. 
A study conducted by Her Majesty’s Inspectorate of Prisons 
(HMIP) reports about cases in the United Kingdom in which 
prisoners, referred to as ‘spice pigs’, are used to test new 
synthetic cannabinoids, to find out what quantities are safe 
and what effects can be marketed (HMIP, 2015b).
Interestingly, anecdotal reports also exist that some 
prisoners with histories of drug use deliberately avoid 
using NPS when they have access to them. Examples 
mentioned include people who have experienced or 
witnessed adverse effects and those who refrain from NPS 
use because of the poor reputation that exists about these 
drugs outside of the prison setting in some countries.
I  Complex set of drivers
Specific motivations for using NPS in prison include coping 
and self-medication purposes, the particular effects of the 
drug themselves, the perceived legal status of NPS, the 
fact that NPS are rarely included and hard to detect in 
routine drug tests, high profits for dealers, and reduced 
availability of illicit drugs.
It has been suggested that people in prison may use NPS 
for the same reason they use other substances in prison, 
principally to escape reality, boredom and the routine of 
prison life. Use of synthetic cannabinoids in prison has 
been identified in the literature as ‘a bird killer’ (1), in that it 
deadens time in prison (Blackman and Bradley, 2017; User 
Voice, 2016). Closely related to this is the use of synthetic 
cannabinoids and other NPS for self-medication purposes 
or as compensation for perceived under-medication, to 
cope with feelings of depression or to feel less anxious or 
stressed. In this context the often powerful or strong 
psychoactive effects reported by users of synthetic 
cannabinoids appears to be important. Dependence has 
been identified as another motivation for use, with some 
prisoners describing how their patterns of use were 
habitual (Ralphs et al., 2017). It has also been reported 
that synthetic cannabinoids may sometimes be used by 
those withdrawing from a dependency from other 
substances such as heroin when entering prison.
In contrast to illicit drugs, one of the main drivers reported 
for the consumption of synthetic cannabinoids in prison is 
the perceived legal status and avoidance of positive drug 
tests (Reuter and Pardo, 2016). Researchers have found 
switching to substances that are more difficult to detect 
— or not detectable — by routine drug tests to be common 
practice in prison environments (Ralphs et al., 2017). It has 
been argued this is an important driver for consumption of 
synthetic cannabinoids among the prison population, as 
well as the fact that these substances are odourless, as 
opposed to cannabis, and therefore use is more likely to go 
undetected by prison staff. Similarly, the challenges in 
detecting synthetic cannabinoids and other NPS when 
brought into prison may be an important driver behind 
their availability in prison. Sniffer dogs are not trained to 
recognise the many different types of NPS, while the 
impregnation of the drugs into paper and textiles (see 
below) also represents a considerable challenge to its 
detection by prison staff.
I  Supply of NPS to prisons
The study found that some methods for bringing NPS into 
prisons are similar to those used for established drugs, 
while other methods appear to have been specifically 
developed for the supply of NPS.
A supply route reported by several different countries is 
the ‘throw-over’ method, whereby drugs are thrown over 
the prison wall, sometimes as a simple package, but also 
hidden in other substances. Examples of these include 
oranges, carcasses of birds or as a package with fishhooks 
attached, allowing prisoners to more easily retrieve (‘fish’) 
the package from the courtyard.
(1) Bird is a term used to describe a prison sentence.
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Recent years have seen reports of NPS-packages being 
delivered by ‘drones’ in prisons in Germany, Poland and the 
United Kingdom. The use of drones is not reported to be 
exclusively related to the supply of NPS, but also as an 
innovative method for supplying all kinds of commodities 
into prison (such as illicit drugs and mobile phones).
The use of people visiting prisons for a variety of legitimate 
reasons to bring in NPS was reported by most countries as 
a common supply mechanism. The most frequent one 
being the smuggling by visitors who conceal the substance 
in their body and transfer it during contact with the 
detained. The use of external subcontractors has also been 
identified as an enabler for the supply of NPS in prison: 
cleaning companies, waste disposal trucks and canteen 
distributors have been reported by countries as potential 
sources of supply. Distribution through the prison canteen 
was reported as a common supply route: pre-sealed food 
packages, such as coffee, instant noodles or crackers, may 
be used to conceal NPS.
Synthetic cannabinoids and synthetic opioids can easily be 
dissolved in a solvent, such as acetone, and can be 
sprayed onto paper and tobacco or impregnated into 
textiles (Ford and Berg, 2018). The sending of postal 
packages or letters with NPS sprayed on the paper has 
been identified as a method for bringing NPS into prisons 
in a number of countries (Finland, Germany, Hungary, 
Lithuania, Poland, Sweden, United Kingdom). One of the 
health risks associated with NPS in this form is the 
possible occurrence of so-called ‘hot-spots’ — areas on 
the paper that contain a high concentration of the active 
compound and which may be linked to an elevated risk of 
overdose. Anecdotal information from the United Kingdom 
also points at a possible increase in the use of liquid NPS 
in vaping pens, which may be a possible adaptation to the 
recently implemented smoking ban in UK prisons.
The profit motive is an important driver for bringing NPS 
into prison. A product containing synthetic cannabinoids is 
not complicated to manufacture, and it can be sold at 
a substantial profit outside prison (Surmont et al., 2017). 
This makes it an attractive substance to produce and 
supply to prisons, where prohibited commodities fetch 
higher prices than they do in non-prison environments. 
Some countries reported cases where individual prisoners 
may have deliberately breached their (parole) license by 
bringing NPS into prison in order to take advantage of the 
high profits possible. There is a risk that the potential high 
profits may also attract organised crime groups to engage 
in the supply of NPS in prison.
In conclusion, it appears likely that the combination of high 
profits that can be made from selling NPS in prison 
settings together with the difficulties faced by authorities 
in preventing the trafficking of these drugs into prisons has 
resulted in increased availability and thus easy access to 
them in some prisons. Where NPS are available, prices 
may often be lower than for (often less-available) 
established drugs, and their affordability may be another 
potential motivation for use in the prison environment.
I  NPS-related harms
I  Physical harms and mental health problems
Experts participating in the study reported a wide range of 
physical and mental health harms associated with acute 
intoxication by and chronic consumption of synthetic 
cannabinoids in prison.
Mental health problems reported include psychosis, 
disorientation, suicidal ideation, aggressiveness (including 
self-harm and harms to others), anxiety and depression.
Physical harms reported include nausea, convulsions, 
temporary paralysis, rapid heart rate, cardiovascular 
problems and renal injuries.
Because of the high potency of synthetic cannabinoids, 
even low doses of the substances may lead to intoxication. 
Intoxication may also be related to the lack of experience 
with the substance (composition, quantity needed to 
obtain the desired effect and frequency of use) (EMCDDA, 
2017d). Cases of intoxication requiring hospitalisation 
have been reported in prisons in Germany and the United 
Kingdom and are likely to have occurred in other countries.
Moreover, the chronic use of synthetic cannabinoids has 
been linked with reported dependence and withdrawal 
symptoms (User Voice, 2016). Non-fatal overdoses related 
to NPS, primarily synthetic cannabinoids, have been 
reported by 7 countries (Germany, Finland, Italy, Latvia, 
Lithuania, Poland, United Kingdom). It was also noted that 
the adverse effects of the use of synthetic cannabinoids 
can be long-lasting, and custody and healthcare staff may 
have to manage the consequences for months following 
use (PHE, 2017a). The unintended consequences are also 
evidenced by prisoners increasingly voicing concerns 
about the unpredictable effects.
New psychoactive substances in prison
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A recent issue of concern is whether staff and other people 
in prison can be affected by secondary exposure to 
synthetic cannabinoids, for example by inhaling second-
hand smoke. The high potency of some NPS, particularly 
fentanyl derivatives, also raises a potential risk of 
accidental exposure (although this is unlikely in a prison 
setting); nevertheless, appropriate health and safety 
guidance is important, though this does not appear to exist 
in many countries (EMCDDA, 2017d).
Negative health consequences have also been associated 
with the use of new synthetic opioids in prison. Latvia 
reports that the increasing use of new synthetic opioids in 
prison has been accompanied by more overdoses and an 
increase in injecting, including needle-sharing, in prison. 
Risks associated with the sharing of injecting equipment 
include the contraction of blood-borne infections, such as 
human immunodeficiency virus (HIV) and the hepatitis 
C virus.
Furthermore, the health harms may be exacerbated by 
polydrug use, as NPS are often used in combination with 
other substances, including illicit drugs, alcohol and 
prescribed or misused medicines.
I  NPS-related deaths
Estimating the number of deaths related to NPS in prison, 
as in the general population, is complicated, for a number 
of technical and practical reasons. Prominent among these 
are analytical difficulties related to the lack of reference 
standards for some NPS and the low concentrations at 
which these drugs may be present in biological samples. In 
addition, the polydrug use noted above means that NPS 
may sometimes have played a role in death cases 
associated with heroin, other opioids or stimulants.
Across European countries the number of deaths in prison 
where NPS are involved is therefore difficult to quantify. 
NPS-induced deaths in prison are likely to be under-
reported. Deaths directly or indirectly related to the use of 
NPS in prison have been reported for Germany, Latvia, 
Poland and the United Kingdom. In England and Wales, 
between June 2013 and September 2016, 79 deaths 
occurred in prisons, where the deceased was known or 
strongly suspected to have taken NPS before death, or 
where their NPS use was a key issue during their time in 
prison. Of these 79 deaths, 56 were self-inflicted (Prison 
and Probation Ombudsman, 2017). This underlines the 
possible important role of NPS, particularly synthetic 
cannabinoids, in aggravating existing mental health 
conditions or mental states associated with self-harm.
I  Impact on prison management and the prison environment
The increasing availability and use of NPS in prison also 
appears to have a disturbing impact on prison 
management, including security issues and a disruption of 
the prison regime. Several countries reported an increase 
in levels of violence due to NPS use in prisons (Germany, 
Finland, Poland, Sweden, United Kingdom) and a rise in 
bullying and aggression associated with the use of NPS 
in prison.
Violence and bullying are often a consequence of debts 
among prisoners using NPS, particularly synthetic 
cannabinoids. In the United Kingdom there have been 
reports that debts related to synthetic cannabinoids 
contributed to a general atmosphere of violence and 
aggression in prison, also affecting prisoners not directly 
involved and prison staff.
Both Poland and the United Kingdom reported how the 
increased number of emergency calls related to use of 
synthetic cannabinoids in prisons can have a direct impact 
on prison routines. For every person transferred to 
a hospital, one or more prison staff has to leave the prison 
establishment, with a direct impact on the organisation of 
other activities in the prison, such as education, sport or 
work activities. Reduced opportunities to take part in 
meaningful activities may lead to boredom among 
prisoners; this has been referred to as one of the main 
drivers of substance use in prison. Because of an 
increased number of emergency calls, health professionals 
working in the prison context may also have less time for 
providing the regular prison healthcare. These issues may 
have a direct impact on entire prisons and the well-being of 
their prison population.
I  Responses to NPS in prison
To date, interventions to tackle the problems related to the 
use of NPS in prison have tended to be regulatory, focusing 
on supply reduction and controls. More recently, however, 
health and social interventions have begun to emerge, 
although it appears activity levels in this area remain low 
and information on availability of services or their 
effectiveness is scarce.
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I  Health and social responses
The rapid emergence of novel products means that 
developing supportive health intervention responses is 
challenging, in particular for the prison context (Pirona et 
al., 2017). Only anecdotal reports on the responses to NPS 
in European prisons are currently available, and many 
countries report a lack of appropriate responses.
Some countries report that existing approaches in 
reducing drug use and associated harms among the prison 
population have been adapted to incorporate NPS.
Other countries have started to develop specific 
interventions to respond to NPS problems in the prison 
setting, mainly focusing on synthetic cannabinoids. 
Information initiatives and booklets, workshops or training 
modules focusing on NPS use in prisons have been 
provided or are currently under development for prison 
staff in Germany, France, Hungary, Ireland, Poland, 
Slovenia and the United Kingdom.
In the United Kingdom a wide-ranging programme has 
been undertaken to counteract NPS use in prison. Among 
the measures implemented are legislative changes; 
a smoking ban; the development of new drug tests; 
information campaigns for prisoners; a national strategy 
and action plan to respond to prisoners under the 
influence of NPS; and a new toolkit to support prison 
healthcare and custody staff to address NPS in prison 
(PHE, 2017a, 2017b). The toolkit is an adaptation of an 
existing toolkit on responses to NPS in the community 
(Abdulrahim and Bowden-Jones, 2015) and aims at 
providing guidance for the interventions targeting NPS use 
and related problems in prison. One of the key principles of 
the toolkit is the delivery of support based on observed 
symptoms (‘treat what you see’).
As with responding to drug problems in general, 
partnerships between prison health services and providers 
in the community may prove particularly important in 
supporting the delivery of health education and treatment 
interventions for NPS use and related harms in prisons and 
in ensuring continuity of care upon prison entry and release.
I  Supply reduction responses
Most countries report that no specific supply reduction 
measures are being taken to reduce the availability of NPS 
in prison. The actions taken are those that fall under the 
existing drug supply reduction measures for any substance 
or other illicit commodities: measures such as cell 
searches, visitor control, the use of sniffer dogs and 
infrastructural changes.
In respect to the use of sniffer dogs, some experts 
expressed the need to intensify training for canine units to 
regularly update the substances that can be detected. 
Given the range of substances and the difficulties inherent 
in detecting some NPS, this is likely to be a challenging 
area. In addition, experts highlighted the need for 
continuous training for prison staff to detect not only the 
use of NPS, but also possible modes of supply into prison.
Some countries have changed their general rules and 
regulations to address issues of supply (of NPS) in prison. 
In Poland, prisoners are no longer permitted to receive 
food packages sent by third parties, and they are now only 
allowed to purchase food through the prison canteen 
service. A similar proposal is pending in Hungary, which 
also includes a prohibition on tobacco and toiletries being 
sent by third parties. In the United Kingdom, the Serious 
Crime Act (2015) made the throwing of any object over 
prison walls an offence. Finally, in some prisons in 
Germany, prisoners may only receive photocopies of their 
letters, in order to reduce the risk of them receiving paper 
impregnated with NPS.
I  Key issues
I  A new challenge for prisons in Europe
This trendspotting study strongly supports the concern 
that NPS use and related harms are now becoming an 
important new challenge for the prison system in many 
parts of Europe.
The use of drugs within prisons has historically been 
associated with negative consequences, such as the 
transmission of infections related to the sharing of 
injecting equipment, initiation into drug use and new drug 
use patterns and drug-related violence (Boys et al., 2002; 
Davies, 2004; EMCDDA, 2012). The appearance of NPS in 
prisons appears to pose additional challenges for practice 
and policy in this area.
Worryingly, while reports from most countries indicate 
relatively low levels of NPS use in prisons, this form of drug 
use often appears to be responsible for disproportionately 
high levels of health harms and disruption. The negative 
health impact of NPS use in prison may be exacerbated by 
the high potency of some of the substances, peculiarities 
of the prison setting, including overcrowding, and the 
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unpredictability of some NPS. More generally, harms 
related to NPS, such as increasing overdoses and related 
emergency calls, may have a disturbing knock-on effect on 
the overall prison systems in some European countries. 
They may lead to a cycle in which problems associated 
with NPS occupy staff time, which in turn may impact on 
levels of meaningful activities in prisons, so that prisoners 
spend more time in their cells feeling bored, which may 
even lead to increased levels of substance use and 
other problems.
I  Synthetic cannabinoids as a particular concern for the prison setting
Synthetic cannabinoids appear to be a particular concern 
for prisons across Europe. There is a number of reasons for 
this. They are frequently sold as ‘legal’ replacements for 
cannabis and may be used by young, relatively 
inexperienced users in prison. In addition, a wide range of 
health harms, such as aggressiveness and anxiety, have 
been associated with the use of synthetic cannabinoids, 
which may be aggravated by peculiarities of the prison 
setting, such as overcrowding and prisoners’ pre-existing 
mental health conditions. Given the potential for synthetic 
cannabinoids to trigger mental health issues, reports of 
high levels of consumption among the prison population 
need to be closely monitored, especially because of 
prisoners’ propensity for addiction and pre-existing mental 
health conditions (EMCDDA, 2012; Fazel et al., 2017).
The ways in which synthetic cannabinoids are smuggled 
into prison can also result in additional risks for users. 
When spraying the substance onto paper to avoid 
detection, so-called hot-spots may occur. These are areas 
on the paper with a high concentration of the active 
compound, which may result in an elevated risk of 
overdose. It is likely that health harms and other challenges 
related to the use of synthetic cannabinoids in prison may 
further challenge the already strained prison system in 
some countries.
I  The need to adapt responses to allow for a rapidly changing situation
This study provided a rapid assessment of the current 
situation in respect to NPS use in European prisons and 
current responses in this area. It must be acknowledged 
that this analysis is based on a limited evidence base. 
Moreover, we are commenting on an extremely dynamic 
area, where the potential exists for the situation to evolve 
rapidly. This reflects the rapidly changing and adaptable 
nature of the NPS market more generally. In this context, it 
is important to note that any changes occurring outside of 
the prison setting in the availability and use of NPS are 
also likely to have an impact on the patterns of NPS use 
found, and the associated problems observed, within the 
prison setting.
The information gathered here highlights the importance 
of close monitoring of both drug use and the impact of 
responses, in order to respond to changing drug use 
patterns and the potential unintended consequences of 
responses to drug use or wider changes to prison regimes. 
For example, this study suggests that some individuals 
may initiate NPS use within prison. One of the important 
questions this raises is the possible impact of drug use 
within prison on wider patterns of drug consumption, 
including the continuation of new patterns of use after 
release from custody.
The avoidance of positive drug tests has been suggested 
as motivation for drug users to switch to NPS while in 
prison. Increases in NPS use in prisons may therefore, 
arguably, be an unintended negative consequence of 
random mandatory drug testing programmes in some 
European prisons. Germany and the United Kingdom have 
recently introduced testing for synthetic cannabinoids in 
prison, and the consequences of these measures are still 
to be evaluated. Any testing regime in these settings has to 
take into account the possibility of drug substitution. One 
possible outcome, for example, is that there may be 
displacement from use of synthetic cannabinoids to other 
substances, such as synthetic opioids, which may also be 
extremely harmful. This underlines the importance of 
accompanying the implementation of responses with 
monitoring and evaluation to allow practice to be modified 
where necessary. The introduction of other measures to 
tackle NPS use and supply in prison may similarly lead to 
displacement in types of substances used or new modes 
of supply. It will be important for authorities to be alert for 
such potential changes and assess their impact on overall 
harms to develop measures that are comprehensive and 
effective in order to limit the harms associated with NPS 
use and other forms of drug consumption within the 
prison environment.
I  Definition and data: two linked problems
This study has highlighted a number of problems 
associated with monitoring drug use in the prison 
environment, in particular for NPS, and has shown how 
scarce the information in this field is. The EMCDDA is 
working to improve data quality, in particular in respect to 
national coverage and comparability across Europe 
(EMCDDA, 2014). Studies carried out in European prisons 
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still use different definitions, methodologies and study 
designs. To standardise data collection, the EMCDDA has 
developed the European questionnaire for drug use in 
prisons (EQDP) and accompanying methodological 
guidelines (EMCDDA, 2017e).
Monitoring the use and availability of NPS in prisons 
presents an additional set of challenges: the lack of 
a common definition of what constitutes an NPS and the 
use of NPS as an umbrella term; the large number of 
substances appearing on the market each year; and 
differences in national legislation and regulation. In 
addition, methods that rely on self-reporting are less 
reliable for NPS, as users are often unaware of the actual 
substances consumed. Furthermore, NPS are chemically 
very diverse, and because of the difficulties in analytical 
identification, they may be undetected and under-reported. 
For these reasons caution is necessary when interpreting 
and commenting on time trends and geographical patterns.
I  Conclusion
The research carried out for this study found reports of the 
use of NPS in prison in most of the countries. The study 
also demonstrated that while in most countries the use of 
NPS is currently limited to relatively small numbers of 
prisoners it can be associated with disproportionately high 
levels of harm. The study confirms synthetic cannabinoids 
as the type of NPS most often used in prisons, while 
observing that the variety of NPS used in European prisons 
appears to have increased in recent years. It also adds 
support to the suggestion that different user groups can 
be identifiable in European prisons (from the young, naïve 
users to those with long drug careers); it describes 
different motivations for NPS use in prison and highlights 
the role of innovation for the supply of NPS in prison. Taken 
together, these conclusions, while not being confirmatory, 
are useful for informing a debate on how best to improve 
the monitoring of and responses to NPS use in prison. They 
also raise a number of important questions that merit 
formal research follow-up.
It remains unclear whether the increasing number of 
countries reporting NPS use in prison reflects actual 
changes in NPS use and availability in prison settings or 
improved monitoring efforts. Questions also remain about 
the overall prevalence of NPS use in the prison context 
(complicated by comparability issues), the scope of 
initiation of NPS use in prison, use of NPS in place of 
previously used substances, and the scale and range of 
NPS-related harms, including the number of deaths.
Important questions to explore in the future include: what 
is the impact of the emergence of new psychoactive 
substances on established drug markets in prison? Is there 
any impact of use during imprisonment on use after 
release? Will the use of new (potent) synthetic opioids and 
new benzodiazepines become more common in prison? 
These questions provide a strong incentive to keep a close 
watch on emerging trends in this rapidly developing area, 
which has implications for health both inside and outside 
the prison setting.
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